MLL gene fusions in human leukaemias: in vivo modelling to recapitulate these primary tumourigenic events

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International journal of hematology

• Publication date

  2008-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12185-007-0001-3PMID 18224407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leukaemia lineage specification caused by cell-specific Mll-Enl translocations

  2008cited by this paper
• Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias.

  2008cited by this paper
• A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology

  2006cited by this paper
• The Ews-ERG Fusion Protein Can Initiate Neoplasia from Lineage-Committed Haematopoietic Cells

  2005cited by this paper
• Mll fusions generated by Cre‐loxP‐mediated de novo translocations can induce lineage reassignment in tumorigenesis

  2005cited by this paper
• The invertor knock-in conditional chromosomal translocation mimic

  2004cited by this paper
• MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein

  2003cited by this paper
• The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development

  2003cited by this paper
• Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer.

  2003cited by this paper
• MLL targets SET domain methyltransferase activity to Hox gene promoters.

  2002cited by this paper
• ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation.

  2002influential reference
• Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

  2002cited by this paper
• Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins

  2001cited by this paper
• An Atlas on Chromosomes in Hematological Malignancies. Example: 11q23 and MLL partners

  2001cited by this paper
• Inter‐chromosomal recombination of Mll and Af9 genes mediated by cre‐loxP in mouse development

  2000cited by this paper
• The Mll–AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis

  1999cited by this paper
• The Oncogenic Capacity of HRX-ENL Requires the Transcriptional Transactivation Activity of ENL and the DNA Binding Motifs of HRX

  1998cited by this paper
• Oncogenic transcription factors in the human acute leukemias.

  1997cited by this paper
• An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.

  1996cited by this paper
• 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.

  1994cited by this paper
• Rearrangements involving chromosome band 11Q23 in acute leukaemia.

  1993cited by this paper
• Rearrangements involving chromosome band 11Q23 in acute leukaemia.

  1993cited by this paper
• The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase.

  1992cited by this paper
• Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.

  1989cited by this paper

• Characterization of a more clinically relevant human leukemia xenograft model to examine perturbation of MET/SAM metabolism as a novel therapeutic paradigm for MLL-R leukemia in vivo.

  2019cites this paper
• Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy

  2019cites this paper
• CRISPR-Cas9 technology: applications and human disease modelling.

  2017cites this paper
• CRISPR/Cas9 Technology: Applications and Human Disease Modeling.

  2017cites this paper
• Modeling mixed-lineage-rearranged leukemia initiation in CD34+ cells: a “CRISPR” solution

  2017cites this paper
• Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells

  2015cites this paper
• MLL–AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny

  2013cites this paper
• Cell context in the control of self-renewal and proliferation regulated by MLL1

  2013cites this paper
• The silent mutational landscape of infant MLL‐AF4 pro‐B acute lymphoblastic leukemia

  2013cites this paper
• Frat2 mediates the oncogenic activation of Rac by MLL fusions.

  2012cites this paper
• Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis

  2012cites this paper
• Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes

  2011cites this paper
• Deregulated transcription factors in leukemia

  2011cites this paper
• Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint

  2010cites this paper
• Emergence of two unrelated clones in acute myeloid leukemia with MLL-SEPT9 fusion transcript.

  2010cites this paper
• Caractérisation cytogénétique et clinique des gènes de fusion impliquant MLL

  2010cites this paper
• Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City

  2009cites this paper
• The presence of mature granulocytes/monocytes derived from leukemic cells in MLL-associated leukemia

  2009cites this paper